Recent Stories

Court Upholds Huge Damages Verdict Against ViSalus
August 20, 2020 -- A federal judge recently upheld a $925 million judgement determined by a jury in April 2019 in a clas...8/20/2020

Kristi Hubbard Appointed Younique President
LEHI, Utah, July 8, 2020 -- Kristi Hubbard, a direct-selling executive leader with a strong record of success, has been ...7/10/2020

FTC Sends Warning Letters About False Health Claims
April 24, 2020 - The Federal Trade Commission sent letters warning 10 MLM companies to stop making claims about their pr...4/29/2020

Altair Acquisitions Acquires Wildtree
FRISCO, Texas, April 27, 2020 -- Altair Acquisitions, LLC ("Altair") announced today that it has acquired all of the mat...4/29/2020

Pampered Chef Partners with the American Cancer Society to Support Front-Line Workers
Pampered Chef and the American Cancer Society have announced they are partnering to support free temporary housing for f...4/29/2020

Source: Npros 9/13/2012

FDA Sends Warning Letter to Regeneca

Irvine, CA -- The FDA sent Regeneca, Inc. a letter informing it that supplements containing DMAA (1,3-dimethylamylamine), such as the company's product RegeneSlim, cannot be legally marketed in the United States without the submission of a new dietary ingredient (NDI) notification to FDA.

According to the Dietary Supplement Health and Education Act of 1995, an NDI must show that ingredient has a history of use and evidence that establishes that the ingredient is reasonably expected to be safe when used as recommended. The letter also stated that even if the required NDI notification had been submitted, the agency has no evidence that establishes DMAA as reasonably expected to be safe, saying that "to the best of FDA's knowledge, there is no history of use or other evidence of safety establishing that dimethylamylamine [DMAA] will reasonably be expected to be safe as a dietary ingredient. In fact, dimethylamylamine narrows the blood vessels and arteries, which increases cardiovascular resistance and frequently leads to elevated blood pressure. This rise in blood pressure may increase the work of the heart such that it could precipitate a cardiovascular event, which could range from shortness of breath to tightening of the chest and/or a possible myocardial infarction (heart attack)."

The letter closed with a warning that if Regeneca didn't immediately cease distribution of RegeneSlim, the agency could seize the product and file an injunction against the company.

View Regeneca Review

Related News

Regeneca Shutting Down

Regeneca Worldwide has been ordered to cease operations by the Department of Justice, which filed a consent decree of permanent injunction against the company and its CEO, Matthew Nicosia, alleging that they violated the Federal Food, Drug and Cosmetic Act (FDCA) by manufacturing and distributing Re... Read More...

Regeneca Given Distribution Rights for CardioMap

Cottonwood Heights, UT June 11, 2015 -- Regeneca Worldwide has entered into an exclusive distribution agreement with VE Science Technologies LLC, the creators of the CardioMap heart screening and monitor device, for the network marketing industry.

'We are very excited about this deal, as the ... Read More...

Regeneca Worldwide Announces New President

Cottonwood Heights, UT May 14, 2015 -- Regeneca Worldwide has concluded their search for a new President and are pleased to announce that Mr. Trent Staggs will now lead the company in this role.

'We are thrilled to have Trent Staggs join the Regeneca team and lead the company's operations,' s... Read More...

Regeneca Worldwide Recalls RegenESlim Capsules

Inc. Las Vegas, NV is conducting a voluntary nationwide recall of its RegenESlim appetite control dietary supplement from lot # EX0616R15814 and lot #11414RE5516 because FDA analysis confirmed the presence of DMAA. DMAA is also known as 1,3-dimethylamylamine, methylhexanamine, or geranium extract. ... Read More...